endometriosis and semaglutide Treating Inflammation with GLP-1s Endometriosis as a Systemic and

Dosage ranges Published protocols vary considerably

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition

Telogen effluvium is typically temporary

Key advances The phase III trials ENZAMET, ARCHES and TITAN demonstrated a significant benefit for the addition of enzalutamide or apalutamide to androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer 2,3,4

45 Remarkably, the recent SELECT trial proved the cardiovascular efficacy of subcutaneous semaglutide in reducing the primary cardiovascular composite endpoint (death from cardiovascular causes, non-fatal MI or non-fatal stroke) in both overweight and obese patients with established atherosclerotic CVD